BeyondSpring (BYSI) to Release Quarterly Earnings on Tuesday

BeyondSpring (NASDAQ:BYSI) is expected to be issuing its Q4 2025 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.54) per share and revenue of $8.7670 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, April 16, 2026 at 9:30 AM ET.

BeyondSpring (NASDAQ:BYSI) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.49.

BeyondSpring Trading Down 5.0%

BYSI traded down $0.08 during midday trading on Tuesday, reaching $1.44. The company’s stock had a trading volume of 22,946 shares, compared to its average volume of 23,926. The firm has a market capitalization of $59.01 million, a price-to-earnings ratio of -9.57 and a beta of 0.41. BeyondSpring has a 1 year low of $1.21 and a 1 year high of $3.44. The stock’s 50-day moving average is $1.60 and its 200-day moving average is $1.72.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of BeyondSpring in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, BeyondSpring currently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BeyondSpring stock. State Street Corp bought a new position in BeyondSpring Inc. (NASDAQ:BYSI) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned approximately 0.57% of BeyondSpring as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 40.29% of the company’s stock.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.